MOESM1 of Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

Nguyen, Quan; Sepah, Yasir; Berger, Brian; Brown, David; Do, Diana; Garcia-Hernandez, Alberto; Patel, Sunil; Rahhal, Firas; Shildkrot, Yevgeniy; Renfurm, Ronny

doi:10.6084/m9.figshare.9202847.v1

40942_2019_178_MOESM1_ESM.pdf (118.59 kB)

MOESM1 of Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

journal contribution

posted on 2019-08-01, 04:35 authored by Quan Nguyen, Yasir Sepah, Brian Berger, David Brown, Diana Do, Alberto Garcia-Hernandez, Sunil Patel, Firas Rahhal, Yevgeniy Shildkrot, Ronny Renfurm

Additional file 1: TableÂ S1. Baseline characteristics (safety analysis set).

Funding

Astellas Pharma, Inc., Northbrook, IL

History

Usage metrics

Read the peer-reviewed publication

Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

International Journal of Retina and Vitreous

Keywords

ASP8232 VAP-1 inhibitor Center-involved diabetic macular edema Central subfield thickness Ranibizumab Clinical trial

Licence

CC BY + CC0

MOESM1 of Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

Funding

Astellas Pharma, Inc., Northbrook, IL

History

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports